Navigation Links
Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
Date:12/21/2007

ation (FDA). These results provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

About the phase 3 study: The phase 3 study investigating PI-88 as a post- resection treatment for hepatocellular carcinoma (HCC, primary liver cancer) following curative resection is a double-blinded, placebo-controlled study, that has been designed to establish the efficacy and safety of PI-88 in the post-resection HCC setting. The trial will recruit approximately 600 patients at about 60 hospitals in 14 countries. Disease-free survival will be the primary endpoint. Upon completion of this trial, the results are expected to form the basis of global regulatory filings for PI-88.

About Progen: Progen Pharmaceuticals Limited is an Australia-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.

This press release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PI-166 and other drugs, future capitals needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company's filings with the Australian Stock Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Progen Pharmaceuticals Announces Fiscal 2007 Financial Results
3. Progen Announces PI-88 Phase 2 Lung Cancer Results
4. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
5. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
6. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
7. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
10. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
11. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a ... cardiovascular disease and overall health is pleased to provide you ... its outlook for 2015 from the CEO, Mr. Eugene ... would like to take this opportunity to share with you ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Nov. 10, 2010 NeoStem, Inc. (NYSE Amex: ... U.S. and China, announced today that Chief Executive Officer Robin ... developments at the Company at the LifeTech Capital Miami Medical ... Miami on November 12, 2010. In addition, Dr. Smith has ...
... Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: ... subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), has been ... the United States Internal Revenue Service (IRS) and the ... the Patient Protection and Affordable Care Act of ...
Cached Medicine Technology:NeoStem to Present at LifeTech Capital Miami Medical Investors Conference 2Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants 2Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:12/26/2014)... 2014 The US represents the largest market ... 2013, GlobalData’s forecast estimates that sales of branded therapies were ... to the high incidence of the disease, high drug treatment ... and China. Increased sales of CRC therapies over the forecast ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... Christine Mummery, one of the worlds leading heart stem cell ... Dame Anne McLaren in the keynote lecture of the inaugural ... McLaren was an early pioneer of the study of embryonic ... of IVF treatments and stem cell techniques. , Prof Mummery ...
... natural fatty acids that is sometimes used as a weight-loss ... substances to prevent health problems that can follow rapid weight ... a compound naturally found in some meat and dairy products, ... a recent study in mice found that the hormone leptin ...
... to Complement Renowned Laboratory Information System, ... Inc. (OTC Bulletin Board: GLOB), an international,e-Health, ... its,Wyndgate Technologies(R) (Wyndgate) division has formed a ... CERN ), a,leading provider of healthcare ...
... MIAMI, April 9, 2008 Eurosport Active World, ... World, Corp. and,Eagle International Holdings Group, Inc. have ... Corp., whose common stock,trades on the "Pink Sheets" ... Inc. have merged. Subsequent to a 1000:1 reverse ...
... could be missed, harming long-term survival, study suggests , , ... analysis of breast cancer patient survival suggests it might ... node biopsies. , A team of New York City ... to be free of cancerous cells in their sentinel ...
... April 9, 2008 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited ... marketer of medical devices in China with a ... Cheng, Mindray,s,executive vice president of strategic development and ... the JPMorgan 4th Annual China,Conference to be held ...
Cached Medicine News:Health News:Heart stem cell scientist to honor pioneering woman scientist in keynote speech 2Health News:Dietary oil may need help in avoiding any side effects of weight loss 2Health News:Dietary oil may need help in avoiding any side effects of weight loss 3Health News:Global Med Technologies(R), Inc. and Cerner Announce Strategic Alliance 2Health News:Global Med Technologies(R), Inc. and Cerner Announce Strategic Alliance 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 2Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 3Health News:Breast Cancer Lymph Node Biopsy May Need Closer Look 4Health News:Mindray to Attend the JPMorgan 4th Annual China Conference 2
... The Calypte AwareTM HIV-1/2 OMT test ... in vitro immunoassay for the,detection of antibodies ... and Type 2 (HIV-2) in human oral,mucosal ... as a point-of-care aid in the clinical ...
... the first HbA1c control available with intact ... HbA1c procedure including the lysing of the ... ready-to-use liquid control with an open-vial stability ... of six months when refrigerated. A1c-Cellular is ...
...
...
Medicine Products: